Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
PXL065 demonstrated significant benefits in a HCM mouse model preventing pathological myocardial remodeling, including hypertrophy and fibrosis in the heart
Presentation of detailed results from preclinical study on Sept 1st, 2025, 11:15 am CEST, at the European Society of Cardiology 2025
Findings support the clinical development of PXL065 as a potential disease- modifying treatment for symptomatic and asymptomatic HCM patients
LYON, France, May 26, 2025--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the abstract featuring previously announced preclinical data demonstrating positive results for PXL065, the deuterium-stabilized R-enantiomer of pioglitazone, in hypertrophic cardiomyopathy1, has been accepted for presentation at the 2025 edition of the European Society of Cardiology (ESC) Congress (link), to be held jointly with World Congress of Cardiology, on September 1st, 2025 at 11:15 am CEST, in Madrid, Spain.
Prof. Dr. Cordula Wolf, Director of the Center for Rare Congenital Heart Diseases at the TUM University Hospital German Heart Center, stated: "The compelling results obtained in this study illustrate the potential of PXL065 in HCM, the most common genetic cardiac disorder. Current treatments have important limitations in efficacy, safety, or patient applicability. There is a clear unmet need for safe and effective disease-modifying therapies."
Thomas Kuhn, CEO of Poxel, added: "We are pleased to have the data with PXL065 in HCM be presented at one of the world's leading forums for cardiovascular science and medicine, which underscores both the quality and relevance of these findings. We look forward to further supporting PXL065 development for the treatment of HCM based on these promising results."
Hypertrophic Cardiomyopathy (HCM) is a genetic disorder marked by myocardial hypertrophy, cardiac fibrosis, ventricular dysfunction, arrhythmias, and an increased risk of sudden cardiac death. It is caused by mutations in sarcomere protein genes, leading to altered cell metabolism, including oxidative stress and mitochondrial dysfunction. The estimated prevalence of HCM is 0.2%, or 1/500 adults, and its incidence is around 5 per 100,000 person-years.
In connection with the mechanism of action of PXL065 on the inhibition of the mitochondrial pyruvate carrier (MPC) and on the inhibition of Acyl CoA Synthetase 4 (ACSL4) thus acting on oxidative stress, inflammation and fibrosis, PXL065 was successfully assessed in an established mouse model of hypertrophic cardiomyopathy.
This preclinical study was funded by the German Center for Cardiovascular Research (DZHK) and conducted at the TUM University Hospital German Heart Center by leading HCM expert Prof. Dr. Cordula Wolf. Poxel and the TUM University Hospital German Heart Center collaborated on the pre-clinical study based on Poxel's existing data and patent portfolio on PXL065 and prior research conducted by Prof. Dr. Cordula Wolf and her group on the disease mechanisms and therapeutic use of TZD's in HCM.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
1 Press release as of March 20, 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526341087/en/
Contacts
Investor relations / Media NewCapAurélie Manavarere, Théo Martin / Arthur Rouilléinvestors@poxelpharma.com +33 1 44 71 94 94
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
L'Oreal buys British skincare brand Medik8
PARIS/LONDON (Reuters) - L'Oreal is to acquire British skincare brand Medik8, its owner, Britain-based private equity firm Inflexion, said on Monday, boosting the French cosmetics giant's offering in the fast-growing dermatological skincare market. The size of the deal was not disclosed. Medik8 focuses on vitamin A-based anti-ageing creams and serums. "The partnership with L'Oreal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8," the private equity firm said in a statement. L'Oreal's dermatological beauty division, which includes major brands like CeraVe, La Roche-Posay, and SkinCeuticals, has been its fastest growing in recent years, reaching revenues of 7 billion euros ($7.99 billion) last year, after growing almost 10% on the year before. The business, which also has the highest profit margin among its four divisions, has boomed on growing consumer interest in science-backed products, though growth has slowed recently due to rising competition. L'Oreal executives said this year they were pursuing acquisitions and looking to revive flagging growth. The company acquired Korean skincare brand, Dr.G, in December and also bought a minority stake in Oman-based perfume house Amourage last year. ($1 = 0.8757 euros) Sign in to access your portfolio
Medscape
an hour ago
- Medscape
Lysosomal Iron Catalyzes Cell Death in Resistant Cancers
A team from French research institutes Centre national de la recherche scientifique (CNRS), Institut Curie, and Institut national de la santé et de la recherche médicale (Inserm) has discovered a new class of molecules capable of inducing the death of cancer cells that are resistant to standard treatments. The study was published in Nature on May 7. Harnessing Iron's Properties in Cancer Cells 'In certain cancers, such as pancreatic cancer or sarcomas, therapeutic options are relatively limited,' Raphaël Rodriguez, research director at CNRS and co-author of the study, told Medscape's French edition . Current cancer treatments mainly target primary tumor cells but often fail to eliminate cells with metastatic potential, which are responsible for 70% of cancer-related deaths. To address this, the team developed a new class of molecules — phospholipid degraders — designed to destroy cancer cell membranes and trigger cell death via ferroptosis. 'We used the properties of iron in cancer cells with metastatic potential. These cells express high levels of the CD44 protein on their surface, which allows them to internalize iron — a resource they need to transform and adapt to standard treatments,' Rodriguez explained. This transformation, however, also makes them more vulnerable to ferroptosis, a form of cell death catalyzed by iron. Within lysosomes — the small organelles that break down cellular debris and foreign material — iron reacts with hydrogen peroxide, generating oxygen radicals. These radicals damage lysosomal membranes and initiate a chain reaction that spreads throughout the cell, leading to the formation of peroxidized lipids in the membranes of other organelles and ultimately causing cell death. 'We were the first to link cancer, adaptability, and vulnerability to ferroptosis. Cancer cells can adapt, but they don't have a thousand identities. They have two: one that proliferates and one that spreads. Today, we target proliferation. We also need to target dissemination,' said Rodriguez. Phospholipid Degraders The researchers developed phospholipid degraders that activate ferroptosis. These molecules contain one segment that targets the cell membrane, enabling penetration and accumulation in lysosomes. A second segment enhances iron reactivity in these compartments of pro-metastatic cancer cells, triggering ferroptosis. The molecules, named fentomycin-1 (Fento-1), were made fluorescent to confirm their lysosomal localization using fluorescence microscopy. 'Ferroptosis results from the cell's inability to repair membrane damage,' Rodriguez summarized. Reduction in Tumor Growth Tested on primary patient-derived cells, tumor organoids, human biopsies, and immunocompetent animal models, these molecules demonstrated greater efficacy than standard treatments. In preclinical models of metastatic breast cancer, Fento-1 led to a significant reduction in tumor growth. It also showed strong cytotoxic effects in biopsies of pancreatic cancers and angiosarcomas. 'The most interesting results come when we combine these molecules with current treatments. The response is even better,' emphasized Rodriguez. 'We're not saying our treatment will replace existing therapies. We need a combination,' he added. The next steps include toxicity studies, followed by clinical trials. 'Industry and investors should be interested in developing this new therapeutic strategy.' This work was supported by the Ligue Contre le Cancer (Les équipes labellisées), the European Union's Horizon 2020 research and innovation programme, Fondation pour la Recherche Médicale, Fondation Charles Defforey - Institut de France, Klaus Grohe Foundation, Institut National du Cancer, Région Île-de-France, the French National Research Agency, Fondation Bettencourt Schueller, CNRS, Institut Curie, and Inserm.
Yahoo
an hour ago
- Yahoo
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to 48 months. This shelf-life extension applies to the 50mg tablet strength of MASIVET® currently available in the EU. MASIVET® is currently approved for the treatment of non-resectable dog mast cell tumours (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor. It is marketed by AB Science and currently available in all EU countries. This extension of the shelf life gives patients, caregivers, and AB Science more flexibility to adjust inventory levels to current and future demand while reducing the risk of product expiration. At the same time, it ensures the continuity of current and future therapies and continues to enable veterinarians to provide their patients with the best available treatment. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB Science Financial Communication & Media Relations investors@ Attachment Masivet Shelf Life VENG VFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
